Brevan Howard Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Brevan Howard Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-125,049	Closed	-$2.42M	–	2333
2026 Q1	$2.42M	Buy	125,049 +65,902	+111%	+$1.06M	0.02%	480
2025 Q4	$955K	Buy	59,147 +3,269	+6%	+$43.3K	0.01%	793
2025 Q3	$681K	Buy	55,878 +42,545	+319%	+$588K	﹤0.01%	1119
2025 Q2	$151K	Buy	+13,333	New	+$163K	﹤0.01%	1756

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brevan Howard Capital Management's KALV Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 125,049 shares — an estimated $2.42M sold.

Brevan Howard Capital Management first reported a position in KALV in Q2 2025 and held it in 4 quarters. The position peaked at $2.42M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Brevan Howard Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 125,049 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.42M.
Brevan Howard Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Brevan Howard Capital Management's KalVista Pharmaceuticals position peaked at $2.42M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.